Artiva Biotherapeutics Announces Board and Compensation Changes
Ticker: ARTV · Form: 8-K · Filed: Jan 29, 2025 · CIK: 1817241
| Field | Detail |
|---|---|
| Company | Artiva Biotherapeutics, Inc. (ARTV) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $40,000, $7,500, $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, filing
TL;DR
Artiva Biotherapeutics filed an 8-K detailing director departures/arrivals and executive pay changes.
AI Summary
Artiva Biotherapeutics, Inc. announced on January 28, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of a director, the election of a new director, and adjustments to compensatory arrangements for certain officers. The filing also includes financial statements and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes, while common, can sometimes precede significant strategic shifts or indicate internal dynamics that warrant closer investor scrutiny.
Key Players & Entities
- Artiva Biotherapeutics, Inc. (company) — Registrant
- January 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices address
FAQ
Who departed from Artiva Biotherapeutics' board of directors?
The filing indicates the departure of a director, but the specific name is not provided in the summary text.
Who was elected to the board of directors at Artiva Biotherapeutics?
The filing states that a new director was elected, but the name is not specified in the provided text.
What other items are included in this Form 8-K filing?
In addition to director and officer information, the filing includes financial statements and exhibits.
What is the principal executive office address for Artiva Biotherapeutics?
The principal executive offices are located at 5505 Morehouse Drive, Suite 100, San Diego, California 92121.
What is the filing date for this Form 8-K?
The filing was made as of January 29, 2025.
Filing Stats: 967 words · 4 min read · ~3 pages · Grade level 10.5 · Accepted 2025-01-29 16:07:29
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share ARTV Nasdaq Glo
- $40,000 — will receive an annual cash retainer of $40,000 for service on the Board and (ii) was g
- $7,500 — will receive an annual cash retainer of $7,500 for services as such. The chair of the
- $15,000 — will receive an annual cash retainer of $15,000 for services as such. The above referen
Filing Documents
- artv-20250128.htm (8-K) — 55KB
- 0000950170-25-010481.txt ( ) — 179KB
- artv-20250128.xsd (EX-101.SCH) — 31KB
- artv-20250128_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Artiva Biotherapeutics, Inc. By: /s/ Fred Aslan Fred Aslan, M.D. President and Chief Executive Officer Dated: January 29, 2025